Prosecution Insights
Last updated: April 19, 2026

Examiner: EMCH, GREGORY S

Tech Center 1600 • Art Units: 1644 1646 1649 1678 1699

This examiner grants 50% of resolved cases

Performance Statistics

49.6%
Allow Rate
-10.4% vs TC avg
652
Total Applications
+43.6%
Interview Lift
1316
Avg Prosecution Days
Based on 615 resolved cases, 2023–2026

Rejection Statute Breakdown

7.5%
§101 Eligibility
19.7%
§102 Novelty
29.7%
§103 Obviousness
22.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17913629 MONOCLONAL ANTIBODIES TO CHEMICALLY-MODIFIED NUCLEIC ACIDS AND USES THEREOF Non-Final OA AMGEN INC.
17629445 IMMUNE CELLS EXPRESSING MODIFIED CELL RECEPTORS AND METHODS OF MAKING Final Rejection CARTHERICS PTY. LTD.
18019228 COMPOSITIONS AND METHODS OF PREDICTING TIME TO ONSET OF LABOR Final Rejection The Board of Trustees of the Leland Stanford Junior University
17314376 SARS-COV-2 IMMUNOASSAY AND MATERIALS THEREFOR Final Rejection BIO-RAD LABORATORIES, INC.
18542382 METHOD FOR TESTING AND SCREENING P38 MAP KINASE MODIFIERS Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
16302429 ACOUSTIC SEPARATION FOR BIOPROCESSING Final Rejection THE CHARLES STARK DRAPER LABORATORY, INC.
17705924 Methods for Detecting Symmetrical Dimethylarginine Non-Final OA IDEXX Laboratories, Inc.
17793319 FLUORESCENTLY-LABELED F-ACTIN PROTEIN BIOSENSORS AND METHODS OF HIGH-THROUGHPUT DRUG DISCOVERY Non-Final OA ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
18956170 METHOD FOR DETECTION OF CELLS BY REPETITIVE STAINING AND DESTAINING Non-Final OA Miltenyi Biotec B.V. & Co. KG
17790876 METHODS FOR INFORMATION TRANSFER AND RELATED KITS Non-Final OA ENCODIA, INC.
17922074 UNBLENDING OF TRANSCRIPTIONAL CONDENSATES IN HUMAN REPEAT EXPANSION DISEASE Non-Final OA Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
17631598 ANALYTICAL METHOD AND IMMUNOLOGICAL TREATMENT FOR BLADDER CANCER Final Rejection Medizinische Hochschule Hannover
18734732 Capture Beads for Use in Assays Non-Final OA Zafrens Inc.
18538543 LUNG CANCER BIOMARKERS Non-Final OA Meso Scale Technologies, LLC.
18118432 DIAGNOSTIC METHODS FOR LIVER DISORDERS Final Rejection Meso Scale Technologies, LLC.
18248505 PROTEOME ANALYSIS IN PULMONARY HYPERTENSION Non-Final OA IMPERIAL COLLEGE INNOVATIONS LIMITED
18025763 Methods of Determining Immune Response Non-Final OA The Council of the Queensland Institute of Medical Research
18532159 ANTIBODIES AND METHODS FOR THE DETECTION OF CELL DEATH Non-Final OA PHARMA CINQ, LLC
18259727 SURFACE ENHANCED RAMAN SPECTROSCOPIC METHODS FOR DETECTING ANALYTES Non-Final OA Johns Hopkins University
18265584 METHOD FOR PREDICTING THE FERTILITY POTENTIAL OF A FEMALE SUBJECT Non-Final OA Rigshospitalet
17605656 METHOD FOR DIAGNOSING ENDOMETRIOSIS, DISEASE STATE MONITORING METHOD, AND KIT Non-Final OA National Institutes of Biomedical Innovation, Health and Nutrition
17257968 Methods for Multicolor Multiplex Imaging Non-Final OA Ultivue, Inc.
18311895 METHODS OF ISOLATING AND DETECTING VIRUSES FROM LIQUID WITH POSSIBILITY OF CONTAINING VIRUSES Non-Final OA JNC CORPORATION
17794768 MUSCLE-TARGETING COMPLEXES AND USES THEREOF IN TREATING MUSCLE ATROPHY Final Rejection Dyne Therapeutics, Inc.
18068872 COMPOSITIONS AND METHODS RELATED TO ACTIVATABLE THERAPEUTIC AGENTS Non-Final OA AMUNIX PHARMACEUTICALS, INC.
18058171 MULTIPLEXED FLUORESCENCE IN SITU HYBRIDIZATION METHOD CAPABLE OF RAPID DETECTION OF BILLIONS OF TARGETS Non-Final OA Kanvas Biosciences, Inc.
17937251 SURFACE FUNCTIONALIZED AFFINITY MEMBRANES Non-Final OA NANOPAREIL, LLC
17692804 COMPOSITION FOR DETECTING OR MEASURING ANALYTES Non-Final OA BERTIS CO., LTD.
17593922 METHOD OF USING FOLLISTATIN IN TYPE 2 DIABETES RISK PREDICTION Final Rejection LUNDOCH DIAGNOSTICS AB

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month